Of the 14 semaglutide-treated patients that developed anti-semaglutide antibodies, 7 patients (0.2% of the overall population) developed antibodies cross-reacting with native GLP-1
This genetic issue caused differences in both weight loss and side effects
This is why tirzepatide is sometimes described as a "dual agonist." It's not simply a stronger version of semaglutide
If youd like to submit a testimonial of your own, please do so
By using the Services, you consent to our use of cookies, web beacons, and similar technologies, including those operated by third parties on our behalf
Additionally, function and expression of Na/H exchanger isoform 3 (NHE3) decreased but there was increased urine flow and sodium excretion in the tested young SHRs